On October 2, 2023 AskAt reported a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) dated September 6, 2023 for an EP4 receptor antagonist use patent for the treatment of cancer, particularly for the use of grapiprant in the treatment of cancer (Press release, AskAt, OCT 2, 2023, View Source [SID1234635558]). The Notice was issued in connection with Application Number 17/201,102. AskAt’s EP4 receptor antagonist cancer use patent (Filing Date: April 22, 2010) has already been granted in Japan, the United States, Europe, Canada, China, Korea, Mexico, Brazil, Russia, and Hong Kong. This will reinforce the protection of a patent in the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!